The Evolution of Medical Affairs into a Truly Data-enabled Function

The Evolution of Data and Analytics in Medical Affairs

In the rapidly evolving landscape of the pharmaceutical industry, Medical Affairs has emerged as a critical function, bridging the gap between research & development, and clinical practice. During this evolution into a key strategic leader within industry, we have also seen more emphasis on data driven strategy development and impact measurement. However, there is still much to do in order for the function to become a truly data driven, strategic leader with consistently demonstrable impact. Medical Affairs should be preparing itself in a way that is able to harness the power of data to drive evidence-based strategy development, stakeholder engagement, and patient centred approaches. In this journey, Medical Affairs will need to up-skill itself on true strategy and demonstrating its impact. These two areas are capabilities that are inconsistent within the function, at best, and at wors largely missing. However, you cannot develop strategic thinking without understanding your situation and you cannot demonstrate your impact without understanding what data you are collecting. This article delves into the current state of data utilisation in Medical Affairs, the potential areas of improvement, and the future prospects of integrated, data-driven strategies.

The Multifaceted Nature of Data in Medical Affairs

Traditionally, Medical Affairs has relied heavily on clinical trial data to inform its strategies. However, in today's interconnected world, the scope of data has expanded significantly. Medical Affairs now has access to a mixture of quantitative and qualitative data sources, including:

• Clinical Data: Results from randomized controlled trials, observational studies, patient surveys, natural history studies etc. can inform future decision making.
• Real-World Evidence: Data from electronic health records, claims databases, patient-reported outcomes, resource utilisation studies etc.
• Market Research: Insights into market trends, competitor analysis, product positioning etc.
• Stakeholder Feedback: Inputs from healthcare professionals (HCPs), key opinion leaders (KOLs), patients, caregivers, payers, providers.
• Digital Engagement Metrics: Analytics from webinars, podcasts, online platforms, patient portals, apps, social listening etc.
• Traditional Insights (non-digital): MSL insights, live medical education event feedback, industry conferences, academic conferences.

Each data type gives a view of the same market through a different lens, each with its advantages and disadvantages. Integrating these data sets into the Medical Affairs strategic planning work-flow and embedding the required capabilities into function will be critical

Navigating the Complex Landscape of Data in Medical Affairs

The pharmaceutical industry, like many other sectors, has witnessed an explosion in the volume and variety of data available. While this data holds the promise of transformative insights, several challenges hinder its full potential, especially in the realm of Medical Affairs. Let's delve deeper into some of these challenges:

1. Data Silos: The Challenge of Fragmented Data

Understanding the Issue: Data silos refer to the isolated storage and management of data, where information from one department or source is not readily accessible to or integrated with other sources. In the context of Medical Affairs, this could mean clinical trial data being stored separately from real-world evidence or market research insights requiring manual integration by individuals without set processes.

Implications:

• Lack of Holistic View: Without a consolidated view of all relevant data, it becomes challenging to derive comprehensive insights without manually sifting through each data source, highlighting key insights and then integrating them with other data sources. For instance, a global Medical Affairs organisation will have access to individual advisory board reports from countries, regions and global meetings as well as MSL insights from the ground. The likelihood is that the insights derived from each country are managed differently and, in some cases, reports aren’t even read in detail. Additionally, MSL insights from “day to day” prescribers will give a different angle to the situation than Key Medical Expert insights derived from advisory boards.
• Operational Inefficiencies: Duplicate data entry, redundant storage, and the need to access multiple systems can lead to increased operational costs and time delays. Additionally, there are challenges with integrating data sources into a single report to aid decision making. This is especially true when thinking about the different needs at country, regional and global level.
• Potential for Miscommunication: Different teams might base their strategies on different data sets, leading to misaligned strategies and potential miscommunication. On the other hand, organisations with centralised strategies led by global teams may have an imbalanced view of the situation because their insights are derived from and dominated by specific countries or regions. This leads to strategies that aren’t fit for everyone and which can be difficult to tailor.

2. Quality and Consistency: Ensuring Reliable Data

Understanding the Issue: The sources of data in Medical Affairs are diverse, ranging from controlled clinical trial settings and real world databases such as registries to MSL insights and advisory boards. Whilst clinical trial data is rigorously monitored and evaluated for reliability and quality, other sources of data, in particular from “real world” settings, can be inconsistent in their reliability.

Implications:

• Potential Biases: Real-world data, especially when self-reported by patients or collected from diverse healthcare settings, can introduce biases. For example, patients might under-report adverse events or non-compliance; physicians might under-report off-label use.
• Data Integrity Concerns: Inconsistent data collection methods, varying standards across sources, and potential data entry errors can compromise data integrity.
• Challenges in Comparative Analysis: Variability in data quality makes it challenging to compare and contrast data from different sources, potentially leading to misleading conclusions depending on the weighting given to each type of data.

3. Interpretation and Application: From Raw Data to Actionable Insights

Understanding the Issue: Raw data, no matter how comprehensive, holds limited value unless it can be translated into actionable insights. This translation requires a combination of technical expertise in data analytics and a deep understanding of the therapeutic area as well as the ability to join the dots across the various datasets.

Implications:

• Need for Specialised Skills: The complexity of data necessitates expertise in both data analytics and the specific therapeutic domain. A mere statistical anomaly might have significant clinical implications. In contrast, focusing on insights from the top specialists or academics in the area may yield strategies that might ignore the challenges faced by general prescribers within the therapy areas.
• Risk of Misinterpretation: Without a proper understanding of the context, there's a risk of misinterpreting the data, which can have serious consequences in terms of strategic choices, and more significantly, patient safety and drug efficacy.
• Strategic Implications: Medical Affairs teams need to ensure that insights derived from data are effectively integrated into strategic planning, stakeholder engagement, and communication strategies. This requires a change in mindset as well as upskilling in specific capabilities within Medical Affairs in order to become a data driven, strategic leader with accountability and demonstrable, measurable impact.

While the challenges posed by data silos, quality concerns, and interpretation complexities are significant, they are not insurmountable. With the right strategies, tools, and expertise, Medical Affairs can harness the full potential of data, driving evidence-based decision-making and enhancing patient outcomes.

Deep Dive: Leveraging Data in Key Domains of Medical Affairs

The integration of data-driven strategies into Medical Affairs is not just a trend but a necessity in today's complex healthcare landscape. By harnessing the power of data, Medical Affairs can enhance its operations, stakeholder engagement, and strategic planning.

1. Strategic Planning: Data-Driven Decision Making

Understanding the Issue: In a competitive market, effective product positioning, launch strategies, and lifecycle management are crucial for success. In the last two decades of Medical Affairs evolution, teams have largely relied on commercial colleagues to set product strategy with Medical strategy adjusted to fit. As we think about data enabled Medical Affairs teams, we should see more and more product level strategies that are driven by Medical Affairs.

Harnessing Data:

• Market Research: Data on market trends, competitor products, and stakeholder preferences can provide valuable insights for strategic planning but has traditionally been managed and “owned” by commercial teams (marketing & sales)

Implications:

• Informed Strategies: By integrating market research data with clinical evidence, Medical Affairs can design strategies that highlight a product's unique value proposition, address market needs, and anticipate challenges. They can make informed choices about “where to play and how to win” for patients.
• Competitive Advantage: Data-driven strategies can provide a competitive edge, ensuring that products are positioned optimally in the market and reach appropriate patients effectively and at the right time. This will lead to better outcomes for patients and better outcomes for the business.

2. Stakeholder Engagement & Scientific Communication: Personalised for Maximum Impact

Understanding the Issue: Stakeholders in the pharmaceutical landscape are diverse, ranging from healthcare professionals (HCPs) and key opinion leaders (KOLs) to patients, caregivers, payers and regulators. Each group has unique needs, preferences, and concerns with Medical Affairs uniquely positioned to engage with all of them.

Harnessing Data:

• Feedback Analysis: By systematically collecting and analysing feedback from various stakeholders, Medical Affairs can identify common concerns, unmet needs, and areas of interest. The organisation can also understand differences between stakeholder, specific challenges and incorporate them into their thinking.
• Digital Engagement Metrics: Metrics such as website visits, webinar attendance, and content engagement levels can provide insights into which topics resonate most with stakeholders.
• Impact Measures: Beyond activity metrics, data driven strategic planning and tactical execution allows for easily identifiable impact measures that are tangible and quantifiable.

Implications:

• Tailored Communication: With a deeper understanding of stakeholder needs, Medical Affairs can design communication strategies that address specific concerns, highlight relevant benefits, and provide value. Leaning on the principles of Closed Loop Marketing, “Closed Loop Scientific Communications (CLSC)” will become the norm in the future, with bespoke educational offerings and bespoke follow up. This cannot happen without a data driven plan. Note: Article on CLSC is coming soon.

• Enhanced Credibility: As a side effect, addressing stakeholder concerns proactively and providing relevant information, Medical Affairs can build trust and credibility with stakeholders with a view to true peer to peer partnership in the journey towards optimising patient outcomes.

3. Evidence Generation: A Holistic View of Product Performance & Patient Outcomes

Understanding the Issue: While clinical trials provide rigorous evidence of a product's efficacy and safety, they often occur in controlled settings that might not reflect real-world scenarios. They are also often restricted by regulatory requirements in terms of endpoints and can miss other data that would allow for better and faster access and implementation (e.g. outcomes data, patient reported outcomes, novel efficacy endpoints).

Harnessing Data:

• Real-World Evidence (RWE): Data from electronic health records, patient registries, observational studies and any other source outside of a controlled setting can provide insights into how a product performs outside of clinical trial, in a wider patient population. Additionally, RWE can give more accurate insights into prescribing practice, resource utilisation, patient preferences.

Implications:

• Comprehensive Understanding: By integrating clinical trial data with RWE, Medical Affairs can gain a more holistic understanding of a product's effectiveness, safety profile, and potential off-label uses. This leads to improved designs of future clinical trials, development of innovative endpoints and more informed strategies.
• Informed Decision Making: This comprehensive evidence base can inform regulatory decisions, reimbursement strategies, and post-market surveillance.

In the era of information, data is a valuable asset that, when harnessed effectively, can drive excellence in Medical Affairs. By integrating data-driven insights into stakeholder engagement, evidence generation, strategic planning, Medical Affairs can enhance its impact, credibility, and value in the healthcare ecosystem.

The Future of Data in Medical Affairs: A Holistic Approach

The pharmaceutical and healthcare sectors are undergoing a transformative shift, driven by the increasing availability and complexity of data. As Medical Affairs stands at the intersection of clinical research, commercial operations, and stakeholder engagement, its role in harnessing this data revolution is paramount. This uniquely positions Medical Affairs to become a driver for the industry as we move away from marketing and sales driven organisations towards those that are science, evidence and patient driven. Here, we delve deeper into the future-oriented, holistic approach to data in Medical Affairs:

1. Integrated Data Platforms: The Backbone of Data-Driven Decision Making

Understanding the Need: With the proliferation of data sources, from clinical trials and real-world evidence to stakeholder feedback and digital engagement metrics, the challenge lies in consolidating this data to derive meaningful insights. As mentioned before, these data sources tend to sit in different places, accessed by multiple platforms with zero interoperability let alone integration.

Potential Solutions:

• Unified Repositories: Creating centralized data repositories that bring together data from diverse sources, ensuring consistency, accessibility, and integrity.
• Interoperability: Ensuring that data platforms can communicate with each other, allowing for the seamless exchange and integration of data across systems.

Implications:

• Holistic Insights: With integrated data platforms, Medical Affairs can gain a 360-degree view of products, stakeholders, and market dynamics, enabling evidence-based decision-making.
• Efficiency: Reducing the time and resources spent on manual data consolidation and ensuring real-time access to updated data.

2. Advanced Analytics: Beyond Traditional Data Analysis

Understanding the Need: The sheer volume and complexity of data available today go beyond the capabilities of traditional analytical methods.

The Solution:

• Artificial Intelligence (AI): Utilising AI platforms to analyse vast, multimodal datasets, identify patterns, and predict future trends. The newer platforms can help to bypass challenges with interoperability, data collection inconsistencies and data quality.
• Machine Learning (ML): Leveraging ML models that continuously learn from new data, refining their predictions and insights over time. Medical Affairs produces new data almost on a daily basis and the ability to “instantly” integrate new information into the system can help to speed up decision making.

Implications:

• Deeper, “real-time” Insights: Advanced analytics can uncover hidden patterns, correlations, and insights that might be missed by traditional methods. With ML technology, new data can be added as they come with overall adjustment of key insights based on weighting. Platforms already exist that allows for MSL insights to be integrated into the wider “dashboard” as they come in. The system analyses and integrates the insight into the overall interpretation giving real time updates.
• Predictive Capabilities: AI and ML can forecast future trends, from patient outcomes and market dynamics to stakeholder behaviours, allowing Medical Affairs to be proactive rather than reactive. Modelling & Simulation techniques have been used within clinical settings for a while now but Medical Affairs teams have rarely used advanced predictive capabilities to understand future trends in the market. A truly data-enabled team would use these predictive capabilities to inform future strategies.
• Optimised Strategies: By understanding the nuances of data, Medical Affairs make better choices and tailor its strategies for maximum impact and efficiency. By understanding data, analysing it appropriately and using deep therapy area knowledge to interpret it appropriately, Medical Affairs teams can identify and define the true problems statements that exist within the disease area; the unmet needs, not only of the patient but also wider stakeholders.

3. Collaborative Ecosystems: Expanding the Horizons of Data Capabilities

Understanding the Need: No organization operates in isolation. To truly harness the potential of data, collaborations that bring together diverse expertise and resources are essential. This is true both internally and externally. Medical Affairs cannot operate in isolation from R&D or commercial operation and the company must not operate in isolation from its customers and end users.

The Solution:

• Partnerships with Academic Institutions: Collaborating with universities and research institutions can provide access to cutting-edge research, analytical methods, and specialised expertise.
• Engagement with Research Organizations: Partnering with organisations that specialise in data collection, analysis, and interpretation can enhance the quality and scope of insights.
• Alliances with Technology Providers: Engaging with tech companies can provide access to advanced analytical tools, platforms, and innovations.
• Fostering Relationships with Regulators and Health Technology Appraisers: Understanding the regulatory and access implications of advanced platforms such as AI will be critical as the industry adopts these technologies.

Implications:

• Enhanced Capabilities: Collaborative ecosystems can provide Medical Affairs with capabilities, tools and platforms that might be beyond the reach of internal teams.
• Innovation: External collaborations can bring fresh perspectives, innovative solutions, and novel approaches to data challenges and strategic problem solving.
• Credibility: Engaging with reputed external partners can enhance the credibility of data insights and strategies.

The future of Medical Affairs is intrinsically linked to its ability to harness the power of data. By adopting a holistic approach that integrates data platforms, leverages advanced analytics, and fosters collaborative ecosystems, Medical Affairs can position itself at the forefront of the healthcare revolution, driving excellence, innovation, and patient-centricity.

Navigating the Data-Driven Transformation in Medical Affairs

The evolution of Medical Affairs into a more data-centric function marks a significant shift in the way Medical Affairs strategy, scientific communications and stakeholder engagement are approached. As we've delved into the intricacies of integrating data and analytics into Medical Affairs capabilities, it's evident that this transformation is not just about adopting new technologies or tools, but about a fundamental change in mindset, capabilities and approach.

The traditional role of Medical Affairs, centered around evidence dissemination and stakeholder education, is expanding. Today, with the influx of diverse data sources—from clinical trials to real-world evidence, from stakeholder feedback to digital engagement metrics—Medical Affairs stands at the intersection of science, technology, and patient care. This unique position offers an opportunity to harness the power of data to drive evidence-based decision-making, tailor communications, and foster deeper, more meaningful stakeholder relationships.

However, this transformation is not without its challenges. Data silos, quality inconsistencies, and the need for specialised skills in data interpretation are just a few of the hurdles that Medical Affairs teams must overcome. Moreover, the ethical and regulatory considerations around data collection and utilisation cannot be understated. Balancing the potential of data-driven insights with the ethical imperatives of patient privacy, consent and regulatory considerations, is a delicate balance, requiring careful navigation and collaboration with appropriate agencies.

Yet, the potential rewards are immense. A data-driven Medical Affairs function can anticipate stakeholder needs, respond to emerging trends, and proactively address gaps in knowledge or understanding. By doing so, Medical Affairs can truly drive a strategic advantage for the business and improved usage of medicines. This, in turn, leads to improved patient outcomes, through better adherence, tailored treatment regimens, appropriate prescribing, leading to enhanced quality of life.

Furthermore, the broader implications of this data-driven transformation extend beyond just Medical Affairs. As healthcare systems globally grapple with challenges of access, affordability, and quality, the insights derived from data can inform policy decisions, shape healthcare delivery models, and influence research priorities. In essence, Medical Affairs, with its data-driven approach, can play a pivotal role in shaping the future of healthcare.

It's clear that the journey to fully integrate data and analytics into Medical Affairs is hugely challenging but also extremely promising. It requires vision, commitment, collaboration, and a continuous learning mindset. But as the medical landscape continues to evolve, driven by advances in research, technology, and patient expectations, Medical Affairs can position itself to lead the way, ensuring that science, data, and patient care converge to deliver the best outcomes. The future of Medical Affairs is not just about data, but about the insights, actions, and impact that data can drive.

Joshi Life Sciences is a coaching and strategic advisory consultancy for the Life Sciences industry set up by Dr Mayur R. Joshi (LinkedIn Profile).

Joshi Life Sciences specialises in career coaching for aspiring and current Medical Affairs professionals to maximise their potential and enhance their impact. We also advise companies looking to enhance their Medical Affairs functions, scale up their teams, build their organisations and we partner with companies that have shared values and vision.

Follow Joshi Life Sciences here to stay updated with latest developments, new partnerships and initiatives and the next article in the series.